Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

NCT03395847 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Gastroesophageal Junction Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
Pathologic Stage III Gastric Cancer AJCC v8
Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIA Gastric Cancer AJCC v8
Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIB Gastric Cancer AJCC v8
Pathologic Stage IIIC Gastric Cancer AJCC v8
Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IV Gastric Cancer AJCC v8
Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
Unresectable Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]